I don’t want to get into a comparison between RAC and other anti-cancer companies as we need everyone working together to solve this extremely difficult problem, beyond pointing out what makes RAC so special from an investment perspective - clinical risk.
Around 3% of new oncology treatments that enter Phase 1 make it through to approval. As an investor in any company developing a new oncology treatment you have less than 1 in 30 chance of investment success, probably less than 1 in 100 when you take into account the risks outside of the clinic.
What attracted me to RAC back in 2019 was that bisantrene had already made it to approval (i.e. it works). While there were still plenty of other risks, the clinical risk was vastly lower.
I don’t want to get into a comparison between RAC and other...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
0.055(3.62%) |
Mkt cap ! $268.4M | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.61 | $1.56 | $106.0K | 67.13K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 649 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 3000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |